Name Matthias Preusser
|Born October 29, 1976 (age 39)
Modling (1976-10-29) |
Institutions Medical University of Vienna
Known for neurooncology, molecular therapy targets, biomarkers.
Notable awards Cardinal-Innitzer-Price (2009), Sibylle Assmus Price for Neuro-Oncology (2009), Advancement award of the city of Vienna (2010, 2013)
Fields Internal medicine, Hematology, Oncology
Melanoma matthias preusser comprehensive cancer center vienna austria
Matthias Preusser (born 29 October 1976, Mödling) is an Austrian oncologist. He is known for his work on neurooncology, Molecular Therapy targets and biomarkers and immunotherapy of cancer.
- Melanoma matthias preusser comprehensive cancer center vienna austria
- Scientific contributions
- Academic memberships
- Honors and awards
Matthias Preusser studied medicine at the Medical University of Vienna, received his Medical Doctor (M.D.) degree in 2003 and holds specialist diplomas for internal medicine, hematology and medical oncology. He achieved habilitation in the field of Experimental Oncology 2009 with the thesis Analysis of Biomarkers in Brain Tumours and in the field of Internal Medicine 2016 with the thesis Personalized Therapy of Cancer. From 2009 he spent stays abroad at the German Cancer Research Center, Heidelberg and at the Memorial Sloan-Kettering Cancer Center, New York. Currently Preusser is consultant and associate professor at the Department of Medicine I, Clinical Division of Oncology at the Medical University of Vienna (head Christoph Zielinski) and director of the research program for brain metastasis. He also serves as coordinator of the brain tumor unit of the Comprehensive Cancer Center – Central Nervous System (CCC-CNS).
Preusser's scientific work deals with the identification of molecular changes with prognostic and therapeutic relevance in brain tumors. His investigations on the significance of the MGMT gene (O-6-methylguanine-DNA methyltransferase), the IDH gene (glioblastoma multiforme) and the BRAF gene and the immunophenotype inlcuing the role of PD-L1 in gliomas and brain metastases are highly cited and he is co-author of the current WHO brain tumor classification, which is considered an international standard reference. The oncologist leads several international clinical studies including a randomised therapy trial on high grade meningioma.
Honors and awards
Publication list PubMed